WASHINGTON , DC-Pentagon officials do not want to discuss the decreasing levels of an anthrax vaccine that could help protect service people headed to the Middle East. Officials will not release the amount of vaccine they have left, but there is only one manufacturer of the medication.
Additionally, this sole manufacturer, Bioport of Lansing, Michigan, is waiting on federal license approval and not currently making the vaccine. The company took over a state facility and began making the vaccine in 1998. They have been trying to license the facility since then, but have had problems with test procedures. Company officials have reportedly said they will provide the necessary information for licensure to the Food and Drug Administration (FDA) by October 15.
The vaccine is of increased importance after the tragic events of September 11. American military troops are on their way to the Middle East, where suspected terrorist Osama bin Laden has reportedly trained his fighters to use chemical weapons.
Anthrax is caused by the spore-forming bacterium Bacillus anthracis, which infects warm-blooded animals most frequently. However, it can also be produced in a dry form for biological warfare and stored in ground particles. Upon inhalation of these particles, humans suffer from respiratory failure and death within a week.
In December, military officials announced they had only 60,000 doses of the vaccine left. They began vaccinating only military personnel who were going to the Persian Gulf for 30 days, or for troops on "special missions." Today, more than 500,000 service members have received a portion of the six-shot vaccination.
Pentagon official have said they think Iraq and other countries have developed biological weapons, such as anthrax. The original plan was to vaccinate all 2.4 million service members against the bacterium.
However, licensure and manufacturing have temporarily delayed this goal.
For more information about anthrax, log onto: www.aomc.org/ComDiseases/Anthrax.html.
Information from www.sfgate.com, www.aomc.org,
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.